ClinicalTrials.govpublic full text
The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer
advanced bladder cancer, time-of-day administration, chronotherapy, circadian rhythm, enfortumab vedotin and pembrolizumab (ev/p), urothelial cancer, chronoimmunotherapy, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 891450
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.